• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE EXCLUDER ILIAC BRANCH ENDOPROSTHESIS; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE EXCLUDER ILIAC BRANCH ENDOPROSTHESIS; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT Back to Search Results
Model Number CEB231210A
Device Problem Disconnection (1171)
Patient Problems Aneurysm (1708); Appropriate Clinical Signs, Symptoms, Conditions Term / Code Not Available (4581)
Event Date 05/17/2021
Event Type  Injury  
Manufacturer Narrative
(b)(4).A review of the manufacturing records for the devices verified that the lots met all pre-release specifications.The device remains implanted and, therefore, was not available for direct evaluation by gore.It should be noted the instructions for use for the gore® excluder® aaa endoprosthesis and the gore® excluder® iliac branch endoprosthesis state ¿adverse events that may occur and / or require intervention include, but are not limited to, endoleak and aneurysm rupture.¿.
 
Event Description
On (b)(6) 2019, a patient underwent endovascular treatment of an abdominal aortic aneurysm using gore® excluder® aaa endoprostheses, gore® excluder® iliac branch endoprostheses and a non-gore manufactured stent graft as a bridging component.On (b)(6) 2021, follow-up examination reportedly identified a pending rupture of the abdominal aortic aneurysm.A distal type iii endoleak (component disconnection) was also reportedly detected between the proximal end of the iliac branch endoprosthesis and the distal end of the non-gore manufactured bridging component.On the same day, the patient underwent an emergency re-intervention procedure whereby a 27mm gore® excluder® contralateral leg component was implanted as an additional bridge leg in the iliac branch endoprosthesis and non-gore manufactured stent.According to the report, procedural imaging showed inadequate seal between the iliac branch endoprosthesis and the 27mm contralateral leg component.Three additional gore® excluder® devices were implanted to reline the stent graft system.The procedure was completed without any further reported complications.The patient tolerated the procedure.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE EXCLUDER ILIAC BRANCH ENDOPROSTHESIS
Type of Device
SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
Manufacturer (Section G)
MEDICAL SILICON VALLEY B/P
2890 de la cruz blvd.
santa clara CA 95050
Manufacturer Contact
damon jackson
1505 n. fourth street
flagstaff, AZ 86004
9285263030
MDR Report Key11886949
MDR Text Key254855547
Report Number3013164176-2021-01182
Device Sequence Number1
Product Code MIH
UDI-Device Identifier00733132635290
UDI-Public00733132635290
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
P020004
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative
Reporter Occupation Physician
Type of Report Initial
Report Date 05/26/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date12/12/2021
Device Model NumberCEB231210A
Device Catalogue NumberCEB231210A
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Initial Date Manufacturer Received 05/17/2021
Initial Date FDA Received05/26/2021
Date Device Manufactured12/13/2018
Is the Device Single Use? Yes
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
Patient Age74 YR
-
-